nach oben

Advances in Therapy

Erschienen in:

06.01.2022 | Review

Role of Exemestane in the Treatment of Estrogen-Receptor-Positive Breast Cancer: A Narrative Review of Recent Evidence

verfasst von: Yongmei Wang, Fanbo Jing, Haibo Wang

Erschienen in: Advances in Therapy | Ausgabe 2/2022

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Breast cancer (BC) is the most common type of cancer diagnosed among women worldwide with an estimated 2.3 million new cases every year. Almost two-thirds of all patients with BC have estrogen receptor-positive (ER+) tumors. In this review, the clinical evidence of exemestane in different treatment settings in ER+ BC is presented and summarized.

Search strategy

A search strategy with the keywords “breast cancer [MeSH Terms]” AND “exemestane [Title/Abstract]” was devised and a search was performed in PubMed.

Results

The efficacy of exemestane in different treatment settings has been established by numerous clinical studies. Exemestane is recommended as an adjuvant treatment in postmenopausal women previously treated with tamoxifen in trials comparing 5 years of tamoxifen with 2–3 years of tamoxifen combined with 2–3 years of exemestane, which proved that treatment with exemestane provided better survival outcomes. Similarly, exemestane could be considered as a safe treatment option for neoadjuvant treatment, prevention of chemotherapy, and treatment of advanced BC either alone or in combination with other targeted therapy drugs in both pre- and postmenopausal women.

Conclusion

Exemestane could be considered as a reasonable therapeutic option in the treatment of ER+ BC at any stage in pre- and postmenopausal women.

Lumachi F, Santeufemia DA, Basso SM. Current medical treatment of estrogen receptor-positive breast cancer. World J Biol Chem. 2015;6:231–9.PubMedPubMedCentralCrossRef

Puhalla S, Bhattacharya S, Davidson NE. Hormonal therapy in breast cancer: A model disease for the personalization of cancer care. Mol Oncol [Internet]. 2012 [cited 2021 Apr 26];6:222–36. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5528370/.

Zucchini G, Geuna E, Milani A, Aversa C, Martinello R, Montemurro F. Clinical utility of exemestane in the treatment of breast cancer. IJWH [Internet]. Dove Press; 2015 [cited 2021 Apr 26];7:551–63. https://www.dovepress.com/clinical-utility-of-exemestane-in-the-treatment-ofnbspbreast-cancernbs-peer-reviewed-fulltext-article-IJWH.

Pistelli M, Mora AD, Ballatore Z, Berardi R. Aromatase inhibitors in premenopausal women with breast cancer: the state of the art and future prospects. Curr Oncol [Internet]. 2018 [cited 2021 Apr 26];25:e168–75. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5927796/.

Smith IE, Dowsett M, Yap Y-S, Walsh G, Lønning PE, Santen RJ, et al. Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines. J Clin Oncol. 2006;24:2444–7.PubMedCrossRef

Choueiri TK, Alemany CA, Abou-Jawde RM, Budd GT. Role of aromatase inhibitors in the treatment of breast cancer. Clin Ther. 2004;26:1199–214.PubMedCrossRef

Brueggemeier RW, Hackett JC, Diaz-Cruz ES. Aromatase inhibitors in the treatment of breast cancer. Endocr Rev. 2005;26:331–45.PubMedCrossRef

Brueggemeier RW. Update on the use of aromatase inhibitors in breast cancer. Expert Opin Pharmacother. 2006;7:1919–30.PubMedCrossRef

Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med. 2003;348:2431–42.PubMedCrossRef

10.

Dutta U, Pant K. Aromatase inhibitors: past, present and future in breast cancer therapy. Med Oncol. 2008;25:113–24.PubMedCrossRef

11.

Howell A, Howell SJ, Clarke R, Anderson E. Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms? J Steroid Biochem Mol Biol. 2001;79:227–37.PubMedCrossRef

12.

Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet. 2005;365:60–2.PubMedCrossRef

13.

Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005;97:1262–71.PubMedCrossRef

14.

Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004;350:1081–92.PubMedCrossRef

15.

Evans TR, Di Salle E, Ornati G, Lassus M, Benedetti MS, Pianezzola E, et al. Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women. Cancer Res. 1992;52:5933–9.PubMed

16.

Judith MB, Lucy SK, Robert EC, John FF, Alan SC, Stephen EJ, et al. Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane study. J Clin Oncol [Internet]. 2011 [cited 2021 May 8];30:709–17. https://europepmc.org/article/med/22042946.

17.

Morden JP, Alvarez I, Bertelli G, Coates AS, Coleman R, Fallowfield L, et al. Long term follow-up of the Intergroup Exemestane Study (IES). J Clin Oncol [Internet]. 2017 [cited 2021 May 6];35:2507–14. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6175047/.

18.

Mamounas EP, Jeong J-H, Wickerham DL, Smith RE, Ganz PA, Land SR, et al. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial. J Clin Oncol. 2008;26:1965–71.PubMedCrossRef

19.

Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Láng I, et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014;371:107–18.PubMedPubMedCentralCrossRef

20.

Francis PA, Pagani O, Fleming GF, Walley BA, Colleoni M, Láng I, et al. Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med. 2018;379:122–37.PubMedPubMedCentralCrossRef

21.

Bernhard J, Luo W, Ribi K, Colleoni M, Burstein HJ, Tondini C, et al. Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials. Lancet Oncol. 2015;16:848–58.PubMedPubMedCentralCrossRef

22.

Pagani O, Francis PA, Fleming GF, Walley BA, Viale G, Colleoni M, et al. Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT. J Clin Oncol [Internet]. 2020 [cited 2021 Jun 30];38:1293–303. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7164485/.

23.

Kittaneh M, Glück S. Exemestane in the adjuvant treatment of breast cancer in postmenopausal women. Breast Cancer (Auckl) [Internet]. 2011 [cited 2021 Apr 28];5:209–26. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3201097/.

24.

Litton JK, Bevers TB, Arun BK. Exemestane in the prevention setting. Ther Adv Med Oncol. 2012;4:107–12.PubMedPubMedCentralCrossRef

25.

van de Velde CJH, Rea D, Seynaeve C, Putter H, Hasenburg A, Vannetzel J-M, et al. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet. 2011;377:321–31.PubMedCrossRef

26.

Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, Bliss J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol. 2010;28:509–18.PubMedCrossRef

27.

De Placido S, Gallo C, De Laurentiis M, Bisagni G, Arpino G, Sarobba MG, et al. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. Lancet Oncol. 2018;19:474–85.PubMedCrossRef

28.

Ellis MJ, Babiera G, Unzeitig GW, Marcom PK, Guenther JM, Deshryver FK, et al. ACOSOG Z1031: a randomized phase II trial comparing exemestane, letrozole, and anastrozole in postmenopausal women with clinical stage II/III estrogen receptor-positive breast cancer. JCO [Internet]. Wolters Kluwer; 2010 [cited 2021 May 5];28:LBA513. https://doi.org/10.1200/jco.2010.28.18_suppl.lba513.

29.

Ellis MJ, Suman VJ, Hoog J, Lin L, Snider J, Prat A, et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype—ACOSOG Z1031. J Clin Oncol [Internet]. 2011 [cited 2021 May 5];29:2342–9. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3107749/.

30.

Barnadas A, Gil M, González S, Tusquets I, Muñoz M, Arcusa A, et al. Exemestane as primary treatment of oestrogen receptor-positive breast cancer in postmenopausal women: a phase II trial. Br J Cancer [Internet]. Nature Publishing Group; 2009 [cited 2021 May 5];100:442–9. https://www.nature.com/articles/6604868.

31.

Hojo T, Kinoshita T, Imoto S, Shimizu C, Isaka H, Ito H, et al. Use of the neo-adjuvant exemestane in post-menopausal estrogen receptor-positive breast cancer: a randomized phase II trial (PTEX46) to investigate the optimal duration of preoperative endocrine therapy. The Breast [Internet]. 2013 [cited 2021 May 5];22:263–7. https://www.sciencedirect.com/science/article/pii/S0960977613000568.

32.

Sato N, Masuda N, Morimoto T, Ueno T, Kanbayashi C, Kaneko K, et al. Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 12 weeks’ exemestane exposure in patients with estrogen receptor-positive breast cancer: A multicenter, open-label, phase II study. Cancer Med. 2019;8:5468–81.PubMedPubMedCentralCrossRef

33.

Decensi A, Dunn BK, Puntoni M, Gennari A, Ford LG. Exemestane for breast cancer prevention: a critical shift? Cancer Discov. 2012;2:25–40.PubMedPubMedCentralCrossRef

34.

Goss PE, Ingle JN, Alés-Martínez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med. 2011;364:2381–91.PubMedCrossRef

35.

Zhang Y, Simondsen K, Kolesar JM. Exemestane for primary prevention of breast cancer in postmenopausal women. Am J Health Syst Pharm. 2012;69:1384–8.PubMedCrossRef

36.

Gatti-Mays ME, Venzon D, Galbo CE, Singer A, Reynolds J, Makariou E, et al. Exemestane use in postmenopausal women at high risk for invasive breast cancer: evaluating biomarkers of efficacy and safety. Cancer Prev Res (Phila). 2016;9:225–33.CrossRef

37.

Visvanathan K, Hurley P, Bantug E, Brown P, Col NF, Cuzick J, et al. Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2013;31:2942–62.PubMedCrossRef

38.

Jiang Z, Li W, Hu X, Zhang Q, Sun T, Cui S, et al. Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20:806–15.PubMedCrossRef

39.

Yardley DA, Ismail-Khan RR, Melichar B, Lichinitser M, Munster PN, Klein PM, et al. Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. J Clin Oncol. 2013;31:2128–35.PubMedPubMedCentralCrossRef

40.

Park YH, Kim T-Y, Kim GM, Kang SY, Park IH, Kim JH, et al. Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2019;20:1750–9.PubMedCrossRef

41.

Bardia A, Hurvitz SA, DeMichele A, Clark AS, Zelnak AB, Yardley DA, et al. Triplet therapy (continuous ribociclib, everolimus, exemestane) in HR+/HER2− advanced breast cancer postprogression on a CDK4/6 inhibitor (TRINITI-1): efficacy, safety, and biomarker results. JCO Wolters Kluwer. 2019;37:1016–1016.

42.

Xu H-B, Liu Y-J, Li L. Aromatase inhibitor versus tamoxifen in postmenopausal woman with advanced breast cancer: a literature-based meta-analysis. Clin Breast Cancer. 2011;11:246–51.PubMedCrossRef

43.

Paridaens RJ, Dirix LY, Beex LV, Nooij M, Cameron DA, Cufer T, et al. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. J Clin Oncol. 2008;26:4883–90.PubMedPubMedCentralCrossRef

44.

Llombart-Cussac A, Ruiz A, Antón A, Barnadas A, Antolín S, Alés-Martínez JE, et al. Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer: final results from the Spanish Breast Cancer Group 2001–03 phase 2 randomized trial. Cancer. 2012;118:241–7.PubMedCrossRef

45.

Lønning PE. Lack of complete cross-resistance between different aromatase inhibitors; a real finding in search for an explanation? Eur J Cancer. 2009;45:527–35.PubMedCrossRef

46.

Beresford M, Tumur I, Chakrabarti J, Barden J, Rao N, Makris A. A qualitative systematic review of the evidence base for non-cross-resistance between steroidal and non-steroidal aromatase inhibitors in metastatic breast cancer. Clin Oncol (R Coll Radiol). 2011;23:209–15.CrossRef

47.

Kim SH, Park IH, Lee H, Lee KS, Nam B-H, Ro J. Efficacy of exemestane after nonsteroidal aromatase inhibitor use in metastatic breast cancer patients. Asian Pac J Cancer Prev. 2012;13:979–83.PubMedCrossRef

48.

Chia S, Gradishar W, Mauriac L, Bines J, Amant F, Federico M, et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol. 2008;26:1664–70.PubMedCrossRef

49.

Johnston SR, Kilburn LS, Ellis P, Dodwell D, Cameron D, Hayward L, et al. Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial. Lancet Oncol. 2013;14:989–98.PubMedCrossRef

50.

Xie Y, Li Y, Zhang Y, Zhang S, Li W, Guan X, et al. Fulvestrant 500 mg versus exemestane in postmenopausal women with metastatic breast cancer resistant to adjuvant nonsteroidal aromatase inhibitors in clinical practice: a multicenter retrospective study. Clinical Breast Cancer [Internet]. 2019 [cited 2021 Jun 29];19:e452–8. https://linkinghub.elsevier.com/retrieve/pii/S1526820918308012.

51.

Li Y, Xie Y, Gong C, Zhao Y, Zhang J, Zhang S, et al. Comparative treatment patterns and outcomes of fulvestrant versus everolimus plus exemestane for postmenopausal metastatic breast cancer resistant to aromatase inhibitors in real-world experience. Ther Clin Risk Manag [Internet]. 2020 [cited 2021 Jun 29];16:607–15. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7335268/.

52.

Yardley DA, Noguchi S, Pritchard KI, Burris HA, Baselga J, Gnant M, et al. Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther. 2013;30:870–84.PubMedPubMedCentralCrossRef

53.

Steger GG, Egle D, Bartsch R, Pfeiler G, Petru E, Greil R, et al. Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2− advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEPAUT. Breast [Internet]. 2020 [cited 2021 Jun 29];50:64–70. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7375626/.

54.

Maass N, Ostermann H, Possinger K, Klein P, Tesch H, Mühlenhoff L, et al. ACT-FASTER, a prospective cohort study exploring treatment patterns with fulvestrant and exemestane in postmenopausal patients with advanced hormone receptor-positive breast cancer under real-life conditions in Germany. Breast Care (Basel) [Internet]. 2019 [cited 2021 Jun 29];14:401–8. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6940445/.

55.

Chen S. An “Omics” approach to determine the mechanisms of acquired aromatase inhibitor resistance. OMICS [Internet]. Mary Ann Liebert, Inc., publishers; 2011 [cited 2021 May 3];15:347–52. https://doi.org/10.1089/omi.2010.0097.

56.

Masri S, Phung S, Wang X, Chen S. Molecular characterization of aromatase inhibitor-resistant, tamoxifen-resistant and LTEDaro cell lines. J Steroid Biochem Mol Biol. 2010;118:277–82.PubMedCrossRef

57.

Wang X, Masri S, Phung S, Chen S. The role of amphiregulin in exemestane-resistant breast cancer cells: evidence of an autocrine loop. Cancer Res. 2008;68:2259–65.PubMedPubMedCentralCrossRef

58.

Mills JN, Rutkovsky AC, Giordano A. Mechanisms of resistance in estrogen receptor positive breast cancer: overcoming resistance to tamoxifen/aromatase inhibitors. Curr Opin Pharmacol [Internet]. 2018 [cited 2021 May 4];41:59–65. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6454890/.

59.

Hole S, Pedersen AM, Lykkesfeldt AE, Yde CW. Aurora kinase A and B as new treatment targets in aromatase inhibitor-resistant breast cancer cells. Breast Cancer Res Treat [Internet]. 2015 [cited 2021 May 4];149:715–26. https://doi.org/10.1007/s10549-015-3284-8.

60.

Niture SK, Khatri R, Jaiswal AK. Regulation of Nrf2-an update. Free Radic Biol Med. 2014;66:36–44.PubMedCrossRef

61.

Khatri R, Shah P, Guha R, Rassool FV, Tomkinson AE, Brodie A, et al. Retraction: aromatase inhibitor-mediated downregulation of INrf2 (Keap1) leads to increased Nrf2 and resistance in breast cancer. Mol Cancer Ther. 2018;17:2491.PubMedPubMedCentralCrossRef

62.

Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med. 2011;62:233–47.PubMedPubMedCentralCrossRef

63.

Amaral C, Lopes A, Varela CL, da Silva ET, Roleira FMF, Correia-da-Silva G, et al. Exemestane metabolites suppress growth of estrogen receptor-positive breast cancer cells by inducing apoptosis and autophagy: a comparative study with Exemestane. Int J Biochem Cell Biol. 2015;69:183–95.PubMedCrossRef

64.

Augusto TV, Correia-da-Silva G, Rodrigues CMP, Teixeira N, Amaral C. Acquired resistance to aromatase inhibitors: where we stand! Endocrine-Related Cancer [Internet]. Bioscientifica Ltd; 2018 [cited 2021 May 4];25:R283–301. https://erc.bioscientifica.com/view/journals/erc/25/5/ERC-17-0425.xml.

65.

Sobral AF, Amaral C, Correia-da-Silva G, Teixeira N. Unravelling exemestane: from biology to clinical prospects. J Steroid Biochem Mol Biol. 2016;163:1–11.PubMedCrossRef

66.

Ma CX, Reinert T, Chmielewska I, Ellis MJ. Mechanisms of aromatase inhibitor resistance. Nat Rev Cancer. 2015;15:261–75.PubMedCrossRef

67.

Chen Z, Yuan Y-C, Wang Y, Liu Z, Chan HJ, Chen S. Down-regulation of programmed cell death 4 (PDCD4) is associated with aromatase inhibitor resistance and a poor prognosis in estrogen receptor-positive breast cancer. Breast Cancer Res Treat. 2015;152:29–39.PubMedPubMedCentralCrossRef

68.

Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, et al. Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet. 2007;369:559–70.PubMedCrossRef

69.

70.

Amir E, Seruga B, Niraula S, Carlsson L, Ocaña A. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst. 2011;103:1299–309.PubMedCrossRef

71.

Kieback DG, Harbeck N, Bauer W, Hadji P, Weyer G, Menschik T, et al. Endometrial effects of exemestane compared to tamoxifen within the Tamoxifen Exemestane Adjuvant Multicenter (TEAM) trial: results of a prospective gynecological ultrasound substudy. Gynecol Oncol. 2010;119:500–5.PubMedCrossRef

72.

Jones SE, Seynaeve C, Hasenburg A, Rae D, Vannetzel J, Paridaens R, et al. Results of the first planned analysis of the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized phase III trial in hormone sensitive postmenopausal early breast cancer. Cancer Res [Internet]. American Association for Cancer Research; 2009 [cited 2021 May 10];69:15. https://cancerres.aacrjournals.org/content/69/2_Supplement/15.

73.

Markopoulos C, Polychronis A, Zobolas V, Xepapadakis G, Papadiamantis J, Koukouras D, et al. The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: preliminary results of the TEAM Greek sub-study. Breast Cancer Res Treat. 2005;93:61–6.PubMedCrossRef

74.

Hadji P, Asmar L, van Nes JGH, Menschik T, Hasenburg A, Kuck J, et al. The effect of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial: a meta-analysis of the US, German, Netherlands, and Belgium sub-studies. J Cancer Res Clin Oncol. 2011;137:1015–25.PubMedCrossRef

75.

Schilder CM, Seynaeve C, Beex LV, Boogerd W, Linn SC, Gundy CM, et al. Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial. J Clin Oncol. 2010;28:1294–300.PubMedCrossRef

76.

Goss PE, Hershman DL, Cheung AM, Ingle JN, Khosla S, Stearns V, et al. Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial. Lancet Oncol. 2014;15:474–82.PubMedPubMedCentralCrossRef

77.

Gnant M, Baselga J, Rugo HS, Noguchi S, Burris HA, Piccart M, et al. Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2. J Natl Cancer Inst. 2013;105:654–63.PubMedPubMedCentralCrossRef

78.

Lønning PE, Geisler J, Krag LE, Erikstein B, Bremnes Y, Hagen AI, et al. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. JCO [Internet]. Wolters Kluwer; 2005 [cited 2021 May 10];23:5126–37. https://doi.org/10.1200/JCO.2005.07.097.

79.

Wang X, Zhu A, Wang J, Ma F, Liu J, Fan Y, et al. Steroidal aromatase inhibitors have a more favorable effect on lipid profiles than nonsteroidal aromatase inhibitors in postmenopausal women with early breast cancer: a prospective cohort study. Ther Adv Med Oncol [Internet]. 2020 [cited 2021 Jun 16];12. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7252381/.

80.

Saini KS, Twelves C. Determining lines of therapy in patients with solid cancers: a proposed new systematic and comprehensive framework. Br J Cancer [Internet]. 2021 [cited 2021 Aug 26];125:155–63. https://www.nature.com/articles/s41416-021-01319-8.

81.

Derks MGM, Blok EJ, Seynaeve C, Nortier JWR, Kranenbarg EM-K, Liefers G-J, et al. Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18:1211–20.PubMedCrossRef

82.

Goss PE, Ingle JN, Pritchard KI, Ellis MJ, Sledge GW, Budd GT, et al. Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27—a randomized controlled phase III trial. J Clin Oncol. 2013;31:1398–404.PubMedPubMedCentralCrossRef

83.

84.

Alba E, Calvo L, Albanell J, De la Haba JR, Arcusa Lanza A, Chacon JI, et al. Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study. Ann Oncol. 2012;23:3069–74.PubMedCrossRef

85.

Semiglazov V, Kletsel A, Semiglazov V, Zhiltzova E, Ivanov V, Dashyan G, et al. Exemestane (E) vs tamoxifen (T) as neoadjuvant endocrine therapy for postmenopausal women with ER+ breast cancer (T2N1–2, T3N0–1, T4N0M0). JCO [Internet]. Wolters Kluwer; 2005 [cited 2021 May 5];23:530. https://doi.org/10.1200/jco.2005.23.16_suppl.530.

86.

Lustberg MB, Povoski SP, Zhao W, Ziegler RM, Sugimoto Y, Ruppert AS, et al. Phase II trial of neoadjuvant exemestane in combination with celecoxib in postmenopausal women who have breast cancer. Clin Breast Cancer. 2011;11:221–7.PubMedPubMedCentralCrossRef

87.

Cigler T, Richardson H, Yaffe MJ, Fabian CJ, Johnston D, Ingle JN, et al. A randomized, placebo-controlled trial (NCIC CTG MAP.2) examining the effects of exemestane on mammographic breast density, bone density, markers of bone metabolism and serum lipid levels in postmenopausal women. Breast Cancer Res Treat. 2011;126:453–61.PubMedCrossRef

88.

Baselga J, Campone M, Piccart M, Burris HA, Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366:520–9.PubMedCrossRef

89.

Jerusalem G, de Boer RH, Hurvitz S, Yardley DA, Kovalenko E, Ejlertsen B, et al. Everolimus plus exemestane vs everolimus or capecitabine monotherapy for estrogen receptor-positive, HER2-negative advanced breast cancer: the BOLERO-6 randomized clinical trial. JAMA Oncol. 2018;4:1367–74.PubMedCrossRef

90.

Robertson JF, Ferrero J-M, Bourgeois H, Kennecke H, de Boer RH, Jacot W, et al. Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial. Lancet Oncol. 2013;14:228–35.PubMedCrossRef

91.

Yamamoto Y, Ishikawa T, Hozumi Y, Ikeda M, Iwata H, Yamashita H, et al. Randomized controlled trial of toremifene 120 mg compared with exemestane 25 mg after prior treatment with a non-steroidal aromatase inhibitor in postmenopausal women with hormone receptor-positive metastatic breast cancer. BMC Cancer. 2013;13:239.PubMedPubMedCentralCrossRef

92.

Bardia A, Hurvitz SA, DeMichele A, Clark AS, Zelnak A, Yardley DA, et al. Phase I/II trial of exemestane, ribociclib, and everolimus in women with HR+/HER2− advanced breast cancer after progression on CDK4/6 inhibitors (TRINITI-1). Clin Cancer Res [Internet]. American Association for Cancer Research; 2021 [cited 2021 Jun 29]. https://clincancerres.aacrjournals.org/content/early/2021/06/18/1078-0432.CCR-20-2114.

93.

Cook MM, Al Rabadi L, Kaempf AJ, Saraceni MM, Savin MA, Mitri ZI. Everolimus plus exemestane treatment in patients with metastatic hormone receptor‐positive breast cancer previously treated with CDK4/6 inhibitor therapy. Oncologist [Internet]. 2021 [cited 2021 Jun 29];26:101–6. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7873317/.

94.

Cazzaniga ME, Airoldi M, Arcangeli V, Artale S, Atzori F, Ballerio A, et al. Efficacy and safety of everolimus and exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: new insights beyond clinical trials. The EVA Study Breast. 2017;35:115–21.PubMed

Titel: Role of Exemestane in the Treatment of Estrogen-Receptor-Positive Breast Cancer: A Narrative Review of Recent Evidence
verfasst von: Yongmei Wang
Fanbo Jing
Haibo Wang
Publikationsdatum: 06.01.2022
Verlag: Springer Healthcare
Erschienen in: Advances in Therapy / Ausgabe 2/2022
Print ISSN: 0741-238X
Elektronische ISSN: 1865-8652
DOI: https://doi.org/10.1007/s12325-021-01924-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Neue S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Schadet Ärger den Gefäßen?

14.05.2024 Arteriosklerose Nachrichten

In einer Studie aus New York wirkte sich Ärger kurzfristig deutlich negativ auf die Endothelfunktion gesunder Probanden aus. Möglicherweise hat dies Einfluss auf die kardiovaskuläre Gesundheit.

Intervallfasten zur Regeneration des Herzmuskels?

14.05.2024 Herzinfarkt Nachrichten

Die Nahrungsaufnahme auf wenige Stunden am Tag zu beschränken, hat möglicherweise einen günstigen Einfluss auf die Prognose nach akutem ST-Hebungsinfarkt. Darauf deutet eine Studie an der Uniklinik in Halle an der Saale hin.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Introduction

Search strategy

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2022

Changes in Platelet Counts and Thrombocytopenia Risk in Patients with Chronic Liver Disease with Different Etiologies Using Real-World Japanese Data

Real-World Efficacy and Safety of Apremilast in Belgian Patients with Psoriatic Arthritis: Results from the Prospective Observational APOLO Study

White Paper on the Value of Time Savings for Patients and Healthcare Providers of Breast Cancer Therapy: The Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection as an Example

Measuring Burden of Illness in Phenylketonuria (PKU): Development of the PKU Symptom Severity and Impacts Scale as a Robust Patient-Reported Outcome

The Epidemiology of Persons Living with Fontan in 2020 and Projections for 2030: Development of an Epidemiology Model Providing Multinational Estimates